BOULDER, CO, VitriVax, Inc., a vaccine formulation technology company, announced it raised a total of $17.25M in Series B financing.
VitriVax, Inc., a vaccine formulation technology company, announced it raised a total of $17.25M in Series B financing. The round was co-led by Adjuvant Capital and RA Capital Management, LP. Proceeds from the financing will be used for the continued development and commercialization of VitriVax's proprietary Atomic Layering Thermostable Antigen and Adjuvant (ALTA) technology.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
